- Caroline Barth appointed as CHRO and member of the Lonza Group Executive Committee
- Caroline brings a wealth of experience from a 25-year multinational career with specific expertise in culture transformation and diversity
- Recent positions include Global Head of Human Resources, Novartis Pharma, and Global Head ad interim of Novartis Pharma Strategy (previously Global HR Head, Technical Operations and Quality, Novartis Pharma)
Lonza today announced the appointment of Caroline Barth as the new Chief Human Resources Officer (CHRO) for Lonza Group. Caroline will also take a place on the Lonza Group Executive Committee.
Group Chairman and CEO ad interim Albert Baehny commented, “We are delighted to welcome Caroline to our leadership team. She brings a wealth of experience from different countries and cultures, alongside specific expertise in the healthcare industry, following a 15-year career with Novartis. Her contribution will extend and enhance our continuing business focus on the pharma and biotech markets.”
Caroline commented, “I am greatly looking forward to the challenges and rewards of leading the Human Resources function for Lonza Group. It is a strategically important time for the HR function as the company continues to pursue its ambitious growth strategy.”
Caroline will commence her new role on 1 May 2020. She will be based in Basel (CH).
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
Lonza is a leading global supplier to the pharmaceutical, biotech and specialty ingredients markets. We work to promote a healthier lifestyle and prevent illness by supporting our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. This is complemented by our broad range of microbial control solutions, which help to create and maintain a healthy environment.
Patients and consumers benefit from how we apply our scientific knowledge and advanced manufacturing technologies to the healthcare, hygiene and fast-moving consumer goods markets and to developing preservation and protection materials.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide (at the end of 2019). The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com.
Lonza Group Ltd.
Münchensteinerstraße 38
CH4002 Basel
Telefon: +41 (61) 3168638
Telefax: +41 (61) 3169638
http://www.lonza.com
Head Public Relations
Telefon: +41 (61) 316-8929
E-Mail: sanna.fowler@lonza.com
Senior Manager Investor Relations
Telefon: +41 (61) 316-8782
E-Mail: kristin.koehler@lonza.com
